Focus
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Focus 4:480-483, Fall 2006
© 2006 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Search for Related Content

CLINICAL SYNTHESIS

Quick Reference FOR PSYCHOPHARMACOLOGY


View this table:
[in this window]
[in a new window]

 


Table 1. Selective Serotonin Reuptake Inhibitors (SSRIs): Overview




View this table:
[in this window]
[in a new window]

 


Table 2. Tricyclic Antidepressants (TCAs): Overview




View this table:
[in this window]
[in a new window]

 


Table 3. Monoamine Oxidase Inhibitors (MAOIs): Overview




View this table:
[in this window]
[in a new window]

 


Table 4. Atypical (Dopamine-Serotonin Antagonist) Antipsychotics: Overview




View this table:
[in this window]
[in a new window]

 


Table 5. Typical (D2 Antagonist) Antipsychotics: Overview




View this table:
[in this window]
[in a new window]

 


Table 6. Lithium Therapy: Overview




View this table:
[in this window]
[in a new window]

 


Table 7. Valproate Therapy: Overview




View this table:
[in this window]
[in a new window]

 


Table 8. Benzodiazepines (e.g., Diazepam, Clonazepam, Alprazolam): Overview




 FOOTNOTES

The tables in this section are from Schatzberg AF, Cole JO, DeBattista C. Manual of Clinical Psychopharmacology Fifth edition. 2005 American Psychiatric Publishing Inc., Arlington, VA

Reprinted with permission.

Editors note: since initial publication of tables reprinted from the Manual of Clinical Psychopharmacology, additional medications have FDA approval. Some of these recent indications include: clonazepam approved for panic disorder; risperidone, quetiapine, ziprasidone, and aripiprazole approved for acute mania. Olanzepine-fluoxetine combination and quetiapine approved for bipolar depression. Lamotrigine approved for the prevention of depression.





This Article
* Full Text (PDF)
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Search for Related Content


Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org